Alka-Seltzer XS

For rapid relief of pain including migraine, headache, period pains, neuralgia, toothache, sore throat.

Symptomatic relief of rheumatic pain, sciatica, lumbago, fibrositis, muscular aches and pains.

Symptomatic relief of influenza, feverishness, feverish colds.

Alka-Seltzer XS is for oral ingestion after dissolution in water. It dissolves more quickly in warm water.

Adults: Two tablets in water. This dose may be repeated every four hours up to four doses in 24 hours but the dosage should not be continued for more than three days without consulting a doctor. Do not exceed the stated dose.

Alka-Seltzer XS should not be given during pregnancy unless clearly necessary. If Alka-Seltzer XS is used, the total caffeine intake (including other sources, e.g. coffee) should not exceed 200 mg/day (not more than 4 tablets in 24 hours).

Do not give to children under 16 years, unless specifically indicated (e.g. for Kawasaki's disease).

Alka-Seltzer XS should not be administered to patients:

• with known hypersensitivity (e.g. bronchospasm, rhinitis, urticaria) to acetylsalicylic acid or other salicylates, paracetamol, caffeine or to any other components of the product.
• with a history of hypersensitivity reactions (e.g. asthma, rhinitis, urticaria) induced by the administration of salicylates, or substances with similar actions, notably non-steroidal anti-inflammatory drugs.
• with active or a history of peptic ulcers.
• with haemorrhagic diathesis such as haemophilia.
• with severe renal failure.
• with severe hepatic failure.
• with severe cardiac failure.
• with severe cardiovascular disease
• with severe uncontrolled hypertension.
• in the third trimester of pregnancy (see section 4.6).
• who are breastfeeding.
• receiving doses of methotrexate at 15mg/week or greater (see section 4.5).

Caution should be exercised in the following cases:

• hypersensitivity to analgesics / anti-inflammatory agents / anti-rheumatics and in the presence of other allergies,
• with a history of gastrointestinal disorders,
• with concomitant treatment with anticoagulants (e.g. coumarin derivatives or heparin) (see section 4.5),
• patients with impaired renal function or patients with impaired cardiovascular circulation (e.g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major haemorrhagic events), since acetylsalicylic acid and paracetamol may further increase the risk of renal impairment and acute renal failure.

Dosing adjustment may be required, in particular in case of severe renal insufficiency (creatinine clearance < 10 mL/min) where the benefit/risk ratio of paracetamol use should be evaluated and dosing adjustment and continuous monitoring must be ensured.
• patients with impaired hepatic function due to disease or infections affecting the liver such as viral hepatitis, or hepatic insufficiency (Child-Pugh < 9). The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease. An elevation of serum alanine aminotransferase (ALT) may occur during the administration of therapeutic doses of paracetamol.
• patients with conditions that increase the hepatic oxidative stress and decrease the hepatic glutathione reserve such as a variety of concomitant drugs (see section 4.5), alcoholism or diabetes mellitus, as it may place the patient at increased risk of hepatic toxicity to paracetamol at therapeutic doses.
• patients suffering from Gilbert syndrome as it may lead to more pronounced hyperbilirubinemia and clinical symptoms thereof such as jaundice.
• patients with hyperthyroidism.
• in the first or second trimester of pregnancy (see section 4.6)

Acetylsalicylic acid may precipitate bronchospasm and induce asthma attacks or other hypersensitivity reactions. Risk factors are pre-existing asthma, hay fever, nasal polyps, or chronic respiratory disease. This also applies to patients exhibiting allergic reactions (e.g. cutaneous reactions, itching, urticaria) to other substances.

Rare cases of acute myocardial ischemia with or without myocardial infarction as part of a hypersensitivity reaction (Kounis syndrome) have been reported in patients treated with acetylsalicylic acid. In the event of confirmed Kounis syndrome due to acetylsalicylic acid, Alka-Seltzer XS should be discontinued immediately.

Due to its inhibitory effect on platelet aggregation which persists for several days after administration, acetylsalicylic acid may lead to an increased bleeding tendency during and after surgical operations (including minor surgeries, e.g. dental extractions).

At low doses, acetylsalicylic acid reduces the excretion of uric acid. This can possibly trigger gout attacks in predisposed patients.

There is a possible association between aspirin and Reye's syndrome when given to children. Reye's syndrome is a very rare disease, which affects the brain and liver, and can be fatal. For this reason aspirin should not be given to children aged under 16 years unless specifically indicated (e.g. Kawasaki's disease).

In patients suffering from severe glucose-6-phosphate dehydrogenase (G6PD) deficiency, acetylsalicylic acid and paracetamol may induce haemolysis or haemolytic anaemia. Factors that may increase the risk of haemolysis are high dosage, fever, or acute infections, for example.

Alka-Seltzer XS contains paracetamol and so other paracetamol-containing preparations should be avoided. The maximum dose of paracetamol for adults is 4g daily.

Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as those using maximum daily doses of paracetamol. Close monitoring, including measurement of urinary 5-oxoproline, is recommended.

Do not exceed the recommended dose. If symptoms persist consult your doctor. Keep out of the reach of children.

Leaflet warning: Talk to a doctor at once if you take too much of this medicine, even if you feel well. This is because too much paracetamol can cause delayed, serious liver damage.

Label warning: Do not take anything else containing paracetamol while taking this medicine. Talk to a doctor at once if you take too much of this medicine, even if you feel well.

This medicinal product contains 472 mg sodium per tablet, equivalent to 23.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Acetylsalicylic acid:

Contraindicated Interactions:

Methotrexate used at doses of 15 mg/week or more:

Increased haematological toxicity of methotrexate (decreased renal clearance of meth­otrexate by anti-inflammatory agents in general and displacement of methotrexate from its plasma protein binding by salicylates) (see section 4.3 Contraindications).

Combinations requiring precautions for use:

Methotrexate, used at doses of less than 15 mg/week:

Increased haematological toxicity of methotrexate (decreased renal clearance of methotrexate by anti‑inflammatory agents in general and displacement of methotrexate from its plasma protein binding by salicylates).

Anticoagulants, thrombolytics/other inhibitors of platelet aggregation/haemostasis:

Increased risk of bleeding.

Other non‑steroidal anti‑inflammatory drugs with salicylates at higher doses:

Increased risk of ulcers and gastrointestinal bleeding due to synergistic effect.

Selective Serotonin Re-uptake Inhibitors (SSRIs):

Increased risk of upper gastrointestinal bleeding due to possibly synergistic effect.

Digoxin:

Plasma concentrations of digoxin are increased due to a decrease in renal excretion.

Antidiabetics, e.g. insulin, sulphonylureas:

Increased hypoglycaemic effect by high doses of acetylsalicylic acid via hypoglycaemic action of acetylsalicylic acid and displacement of sulphonylurea from its plasma protein binding.

Diuretics in combination with acetylsalicylic acid at higher doses:

Decreased glomerular filtration via decreased renal prostaglandin synthesis.

Systemic glucocorticoids, except hydrocortisone used as replacement therapy in Addison's disease:

Decreased blood salicylate levels during corticosteroid treatment and risk of salicy­late overdose after this treatment is stopped via increased elimination of salicylates by corticosteroids.

Corticosteroids:

Potentiate the risk of gastro-intestinal bleeding during concomitant therapy with corticosteroids.

Angiotensin converting enzyme inhibitors (ACE) in combination with acetyl­salicylic acid at higher doses:

Decreased glomerular filtration via inhibition of vasodilatory prostaglandins. Furthermore, decreased antihypertensive effect.

Valproic acid and Phenytoin:

Increased toxicity of valproic acid due to displacement from protein binding sites. Phenytoin is also extensively bound to plasma proteins therefore it can be displaced by acetylsalicylic acid from plasma binding.

Alcohol:

Increased damage to gastro-intestinal mucosa and prolonged bleeding time due to additive effects of acetylsalicylic acid and alcohol.

Uricosurics such as benzbromarone, probenecid:

Decreased uricosuric effect (competition of renal tubular uric acid elimination).

Caffeine

Caffeine antagonizes the sedating effects of many substances such as certain anti-seizure medicines (e.g. Phenobarbital, carbamazepine, valproate), first generation antihistamines (e.g. chlorpheniramine) etc.

Caffeine acts synergistically with the tachycardiac effects of, for example, sympathomimetics, thyroxin, etc.

In case of substances having a broad spectrum of action (e.g. benzodiazepines) the interactions can vary individually and may be unpredictable. These interactions may increase with intake of higher doses of caffeine per day.

Cytochrome P450 1A2 (CYP1A2) is known to be the major enzyme involved in the metabolism of caffeine. Therefore, caffeine has the potential to interact with drugs that are substrates for CYP1A2.

Caffeine reduces the excretion of theophylline.

Oral contraceptives, cimetidine, and disulfiram slow down degradation of caffeine in the liver; barbiturates and smoking accelerate it.

The simultaneous use of gyrase inhibitors of the quinolonecarboxylic acid-type can delay the elimination of caffeine and its metabolite paraxanthine.

Paracetamol

The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by cholestyramine or propantheline.

Caution should be taken when paracetamol is used concomitantly with flucloxacillin as concurrent intake has been associated with high anion gap metabolic acidosis, especially in patients with risks factors (see section 4.4).

Concomitant use of drugs which cause enzyme induction in the liver, e.g. certain hypnotics and antiepileptics (glutethimide, phenobarbital, phenytoin, carbamazepine etc.) or rifampicin may lead to liver damage even after paracetamol doses which would otherwise be harmless.

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding and elevated international normalized ratio (INR). This is due to the interference of paracetamol (or its metabolites) with enzymes involved in vitamin K-dependent coagulation factor synthesis.

Alka-Seltzer XS should not be taken by pregnant or nursing women unless directed by a doctor.

Pregnancy

Acetylsalicylic acid:

Doses of 500 mg/day and above:

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

During the first and second trimester of pregnancy, acetylsalicylic acid should not be given unless clearly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
• cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
• renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
the mother and the neonate, at the end of pregnancy, to:
• possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
• inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently, acetylsalicylic acid at doses of 100 mg/day and higher is contraindicated during the third trimester of pregnancy.

Caffeine

Caffeine studies have not identified an association between congenital malformations and maternal caffeine consumption in humans.

Paracetamol:

Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically needed, patients should follow the advice of their doctor regarding its use.

Breastfeeding

Acetylsalicylic acid:

Breastfeeding is contraindicated at high doses because of the theoretical risk of affecting clotting mechanisms.

The intake of acetylsalicylic acid by breastfeeding patients should be avoided as there is a risk of Reye's syndrome. Regular use of high doses could impair platelet function and produce hypoprothrombinaemia in the infant if neonatal vitamin K stores are low.

Caffeine:

Caffeine and its metabolites pass into breast milk.

Breast-feeding women should limit total caffeine intake to a maximum of 200 mg per day (including caffeine from medicinal products, food and beverages). Excessive caffeine intake may cause restlessness/irritability in the breast-fed infant.

Paracetamol:

Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data on paracetamol does not contraindicate it for breastfeeding.

Fertility

There is some evidence that drugs which inhibit cyclo-oxygenase / prostaglandin synthesis may cause impairment of female fertility by an effect on ovulation. This is reversible on withdrawal of treatment.

None.

Acetylsalicylic acid:

The listed adverse drug reactions are based on spontaneous reports, thus an organization according to CIOMS III categories of frequency is not possible.

Blood and lymphatic system disorders

Increased risk of bleeding (due to effect on platelet aggregation). In the context of bleeding: haemorrhagic anaemia, iron deficiency anaemia with the respective laboratory and clinical signs and symptoms. In the context of glucose-6-phosphate dehydrogenase (G6PD) deficiency: haemolysis, haemolytic anaemia

Immune system disorders

Hypersensitivity, drug hypersensitivity, allergic edema and angioedema, anaphylactic reaction, anaphylactic shock with respective laboratory and clinical manifestations

Nervous system disorders

Cerebral and intracranial haemorrhage, dizziness

Ear and labyrinth disorders

Tinnitus

Cardiac disorders

In the context of severe allergic reactions: cardio-respiratory distress

Kounis syndrome (acute myocardial ischemia with or without myocardial infarction as part of a hypersensitivity reaction, see section 4.4 “Special warnings and precautions for use”) with frequency not known.

Vascular disorders

Haemorrhage, operative haemorrhage, haematoma, muscle haemorrhage

Respiratory, thoracic and mediastinal disorders

Epistaxis, analgesic asthma syndrome, rhinitis, nasal congestion, bronchospasm

Gastrointestinal disorders

Dyspepsia, gastrointestinal pain, abdominal pain, gingival bleeding, gastrointestinal inflammation, gastrointestinal ulcer, gastrointestinal haemorrhage, gastrointestinal ulcer perforation with the respective laboratory and clinical signs and symptoms, nausea, diarrhoea, vomiting

Hepatobiliary disorders

Liver disorder, transaminases increased

Skin and subcutaneous tissue disorders

Rash, urticaria, pruritus, severe skin reactions

Renal and urinary disorders

Impaired renal function

Injury, poisoning and procedural complications

See overdose section

Caffeine

Cardiac disorders

Caffeine in high doses can cause cardiac effects, such as palpitations, flushing, arrhythmias, hypertension, and tachycardia.

Nervous system disorders

The caffeine component can lead to central nervous system effects, such as headache, insomnia, and inner restlessness.

Paracetamol:

The listed adverse drug reactions are based on spontaneous reports, thus an organization according to CIOMS III categories of frequency is not possible.

Blood and lymphatic system disorders:

There have been reports of blood dyscrasias including thrombocytopenia and agranulocytosis, but these were not necessarily causally related to paracetamol.

Hepatobiliary disorders:

Hepatic dysfunction.

Immune system disorders:

Anaphylaxis.

Cutaneous hypersensitivity reactions including, among others, skin rashes and angioedema. Very rare cases of serious skin reactions have been reported.

Respiratory, thoracic and mediastinal disorders:

Bronchospasm.

There have been cases of bronchospasm with paracetamol, but these are more likely in asthmatics sensitive to aspirin or other NSAIDs.

Skin and subcutaneous tissue disorders:

Very rare cases of serious skin reactions have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Paracetamol

Liver damage is possible in adults who have taken 10g or more of paracetamol.

Symptoms

Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.

Management

Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention and any patient who had ingested around 7.5g or more of paracetamol in the preceding 4 hours should undergo gastric lavage. Administration of oral methionine or intravenous N-acetylcysteine which may have a beneficial effect up to at least 48 hours after the overdose, may be required. General supportive measures must be available.

Acetylsalicylic acid

Salicylate poisoning is usually associated with plasma concentrations >350 mg/L (2.5 mmol/L). Most adult deaths occur in patients whose concentrations exceed 700 mg/L (5.1 mmol/L). Single doses less than 100 mg/kg are unlikely to cause serious poisoning.

Symptoms

Common features include vomiting, dehydration, tinnitus, vertigo, deafness, sweating, warm extremities with bounding pulses, increased respiratory rate and hyperventilation. Some degree of acid-base disturbance is present in most cases.

A mixed respiratory alkalosis and metabolic acidosis with normal or high arterial pH (normal or reduced hydrogen ion concentration) is usual in adults and children over the age of four years. In children aged four years or less, a dominant metabolic acidosis with low arterial pH (raised hydrogen ion concentration) is common. Acidosis may increase salicylate transfer across the blood brain barrier.

Uncommon features include haematemesis, hyperpyrexia, hypoglycaemia, hypokalaemia, thrombocytopaenia, increased INR/PTR, intravascular coagulation, renal failure and non-cardiac pulmonary oedema.

Central nervous system features including confusion, disorientation, coma and convulsions are less common in adults than in children.

Management

Give activated charcoal if an adult presents within one hour of ingestion of more than 250 mg/kg. The plasma salicylate concentration should be measured, although the severity of poisoning cannot be determined from this alone and the clinical and biochemical features must be taken into account. Elimination is increased by urinary alkalinisation, which is achieved by the administration of 1.26% sodium bicarbonate. The urine pH should be monitored. Correct metabolic acidosis with intravenous 8.4% sodium bicarbonate (first check serum potassium). Forced diuresis should not be used since it does not enhance salicylate excretion and may cause pulmonary oedema.

Haemodialysis is the treatment of choice for severe poisoning and should be considered in patients with plasma salicylate concentrations >700 mg/L (5.1 mmol/L), or lower concentrations associated with severe clinical or metabolic features. Patients under ten years or over 70 have increased risk of salicylate toxicity and may require dialysis at an earlier stage.

Caffeine

In the event of caffeine overdose, symptomatic treatment of adverse events (e.g., cardiac) is recommended.

The therapeutic uses of Alka-Seltzer XS are based on the following pharmacological properties of the active ingredients:

The buffer converts acetylsalicylic acid to sodium acetylsalicylate and promotes gastric emptying.

Caffeine (1,3,7‑trimethylxanthine) is a xanthine derivative. At therapeutic plasma concentrations, its primary mechanism of action is non‑selective antagonism of adenosine receptors, particularly A1 and A2A, thereby reducing adenosine‑mediated inhibitory signalling in the central nervous system and contributing to CNS stimulation.

Acetylsalicylate is rapidly absorbed from the small intestine after oral ingestion of Alka-Seltzer XS and rapidly distributed to all body tissues.

Acetylsalicylate is hydrolysed to its active primary metabolite salicylic acid and completely excreted in the urine, principally as glucoronic acid and glycine conjugates of salicylic acid, but also as salicylic acid itself. Salicylates are extensively bound to plasma proteins. Peak plasma levels occur at approximately 20 minutes. Following administration of acetylsalicylic acid, salicylic acid can be detected in breast milk, cerebral spinal fluid and synovial fluid. The substance crosses the placenta.

Paracetamol is rapidly absorbed from the upper gastrointestinal tract after oral administration of Alka-Seltzer XS, with the small intestine being an important site of absorption. Peak plasma concentration occurs about 30 minutes to 2 hours after ingestion. It is rapidly distributed throughout the body and is primarily metabolised in the liver with excretion via the kidney. Elimination half-life varies from about 1 to 4 hours. Paracetamol crosses the placental barrier and is present in breast milk.

Effect on ASA/paracetamol pharmacokinetics in the fixed‑dose combination: In a randomized, crossover phase I study (ASA 250 mg / paracetamol 200 mg / caffeine 50 mg), caffeine had no effect on the pharmacokinetics of ASA, salicylic acid, or paracetamol (C_max and AUC within predefined equivalence limits), indicating bioequivalence under fasting conditions. Caffeine is readily absorbed after oral administration and passes readily into the central nervous system and is widely distributed throughout the body.

After administration of a dose of 5 mg/kg body weight, C_max values are reached within 30-40 minutes and results in 9-10 µg/ml. The bioavailability of orally administered caffeine is almost complete.

Plasma protein binding of caffeine varies between 30 and 40% and the volume of distribution is 0.52 – 1.06 l/kg.

Caffeine is distributed in all compartments, crosses quickly the blood-brain-barrier as well as the placental barrier and passes into breast milk.

Half‑life and variability: In adults, the apparent plasma half‑life of caffeine is approximately 3–7 hours, subject to inter‑ and intra‑individual variability. The half‑life may be prolonged (e.g., pregnancy, hepatic impairment, or with CYP1A2 inhibitors including oestrogen‑containing oral contraceptives) and shortened in smokers or with CYP1A2 induction.

Caffeine and its metabolites are mainly eliminated via the kidneys. In 48 h urine, up to 86% of the administered dose were found; only maximal 1.8% were unchanged caffeine. 1-methyluric acid (12 – 38%), 1- methylxanthine (8 – 19%) and 5-acetylamino-6-amino-3-methyl-uracil (15%) are the main metabolites. The faeces contain only 2 – 5% of the dose. The main metabolite is 1.7 dimethyluric acid which amounts to 44% of the total quantity.

Acetylsalicylic acid

The preclinical safety profile of acetylsalicylic acid is well documented.

In animal studies, salicylates caused kidney damage at high dosages but no other organic lesions. Acetylsalicylic acid has been extensively studied in vitro and in vivo for mutagenicity; no relevant evidence of a mutagenic potential was found. The same applies to carcinogenicity studies.

Salicylates have exhibited teratogenic effects in animal studies and a number of different species. Implantation disorders, embryotoxic and foetotoxic effects and impairment of learning ability in the offspring after prenatal exposure have been described.

Caffeine

Caffeine resulted in reproductive effects in the presence of general toxicity in parental rats and mice. Minor effects in sperm motility in male rats and on pup weights and viability at high doses (50mg/kg/day) were observed. The only reproductive effect observed in a Swiss CD mice study was a reduction of liver pups per litter for the F0 generation at oral doses of 88mg/kg/day. A second study in Swiss CD mice concluded that there were slight reductions in male pup numbers, pup viability and adjusted pup weight at daily oral doses of 49 to 93mg/kg caffeine. The teratogenic profile of caffeine is well understood. Foetal exposure during pregnancy has been well described in humans. One study found various teratogenic effects, resorption of foetuses and a reduction in foetal and placental weight in pregnant rats exposed to caffeine. However, subsequent studies have not identified an association between congenital malformations and maternal caffeine consumption in humans.

Paracetamol

Conventional studies using the currently accepted standards for the evaluation of toxicity to reproduction and development are not available.

Citric Acid

Sodium Hydrogen Carbonate

None known.

30 months.

Laminated paper/polyethylene/aluminium surlyn heat sealed foil:

Do not store above 25°C. Store in the original package.

Laminated aluminium/polyethylene surlyn heat sealed foil:

Do not store above 25°C. Store in the original package.

Laminated paper/polyethylene/aluminium surlyn heat sealed foil, or laminated aluminium/polyethylene surlyn heat sealed foil.

Aluminium foil pouches containing one or two tablets. Pack sizes available are 2, 10, 12, 20, and 30 tablets.

None applicable.